Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma

Pediatric Blood and Cancer

Volumn 57, Issue 4, 2011, Pages 554-560

  Koh, Kyung Nam ^a   Park, Meerim ^a   Kim, Bo Eun ^a   Bae, Keun Wook ^a   Kim, Kyung Mo ^a   Im, Ho Joon ^a   Seo, Jong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Alpha fetoprotein; Hepatoblastoma; Liver transplantation; Prognostic factors

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FEMALE; GROUPS BY AGE; HEPATOBLASTOMA; HUMAN; INFANT; LIVER TRANSPLANTATION; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOSIS; TREATMENT FAILURE;

ADOLESCENT; AGE FACTORS; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATOBLASTOMA; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79961178946     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23069     Document Type: Article

References (26)

1. Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev 2010; 36: 360-371.
2. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005; 146: 204-211.
3. Horton JD, Lee S, Brown SR, et al. Survival trends in children with hepatoblastoma. Pediatr Surg Int 2009; 25: 407-412.
4. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002; 95: 172-182.
5. von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997; 33: 1243-1249.
6. Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53: 1016-1022.
7. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma - results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000; 36: 1418-1425.
8. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005; 23: 1245-1252.
9. Gregory JJ Jr., Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs 1999; 57: 463-467.
10. De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer 2008; 44: 545-550.
11. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 1190-1197.
12. Lovvorn HN, 3rd, Ayers D, Zhao Z, et al. Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg 2010; 45: 121-128 (discussion 129).
13. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002; 94: 1111-1120.
14. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18: 2665-2675.
15. Carceller A, Blanchard H, Champagne J, et al. Surgical resection and chemotherapy improve survival rate for patients with hepatoblastoma. J Pediatr Surg 2001; 36: 755-759.
16. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002; 37: 851-856.
17. Davies JQ, de la Hall PM, Kaschula RO, et al. Hepatoblastoma-evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases. J Pediatr Surg 2004; 39: 1321-1327.
18. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol 2002; 20: 3438-3444.
19. Suita S, Tajiri T, Takamatsu H, et al. Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen - a report from the study group for pediatric solid malignant tumors in the Kyushu area. J Pediatr Surg 2004; 39: 195-198.
20. Medary I, Aronson D, Cheung NK, et al. Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Ann Surg Oncol 1996; 3: 521-525.
21. Jung SE, Kim KH, Kim MY, et al. Clinical characteristics and prognosis of patients with hepatoblastoma. World J Surg 2001; 25: 126-130.
22. Park J, Park J, Han S, et al. Clinical study of hepatoblastoma in children. J Korean Surg Soc 2002; 63: 337-341.
23. Nickerson HJ, Silberman TL, McDonald TP. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer 1980; 45: 315-317.
24. Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16: 329-333.
25. Gauthier F, Valayer J, Thai BL, et al. Hepatoblastoma and hepatocarcinoma in children: analysis of a series of 29 cases. J Pediatr Surg 1986; 21: 424-429.
26. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004; 42: 74-83.